[go: up one dir, main page]

MA38485A1 - Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe - Google Patents

Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe

Info

Publication number
MA38485A1
MA38485A1 MA38485A MA38485A MA38485A1 MA 38485 A1 MA38485 A1 MA 38485A1 MA 38485 A MA38485 A MA 38485A MA 38485 A MA38485 A MA 38485A MA 38485 A1 MA38485 A1 MA 38485A1
Authority
MA
Morocco
Prior art keywords
antibodies
cancer
autoimmune diseases
transplant rejection
human anti
Prior art date
Application number
MA38485A
Other languages
English (en)
Inventor
Huawei Qiu
Ronnie Rong Wei
Clark Qun Pan
Rebecca Sendak
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38485A1 publication Critical patent/MA38485A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps anti-cd52 humains et les fragments de liaison à l'antigène de ceux-ci. L'invention concerne aussi des acides nucléiques isolés, des vecteurs recombinés et des cellules hôtes pour fabriquer des anticorps et des fragments. Les anticorps et les fragments peuvent être utilisés dans des applications thérapeutiques pour traiter, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe.
MA38485A 2013-03-15 2014-03-13 Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe MA38485A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
PCT/US2014/026159 WO2014151644A2 (fr) 2013-03-15 2014-03-13 Anticorps anti-cd52

Publications (1)

Publication Number Publication Date
MA38485A1 true MA38485A1 (fr) 2017-06-30

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38485A MA38485A1 (fr) 2013-03-15 2014-03-13 Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe

Country Status (35)

Country Link
US (2) US9708407B2 (fr)
EP (1) EP2970467B1 (fr)
JP (2) JP6482524B2 (fr)
KR (1) KR20150131286A (fr)
CN (1) CN105209495B (fr)
AR (1) AR095199A1 (fr)
AU (1) AU2014233685B2 (fr)
BR (1) BR112015022464A2 (fr)
CA (1) CA2906539A1 (fr)
CL (1) CL2015002705A1 (fr)
CR (1) CR20150547A (fr)
CY (1) CY1121795T1 (fr)
DK (1) DK2970467T3 (fr)
DO (1) DOP2015000211A (fr)
EA (1) EA031730B1 (fr)
ES (1) ES2710976T3 (fr)
GT (1) GT201500267A (fr)
HR (1) HRP20190085T1 (fr)
HU (1) HUE041796T2 (fr)
IL (1) IL241410A0 (fr)
LT (1) LT2970467T (fr)
MA (1) MA38485A1 (fr)
MX (1) MX2015012991A (fr)
NZ (1) NZ631473A (fr)
PE (1) PE20151757A1 (fr)
PH (1) PH12015501932A1 (fr)
PL (1) PL2970467T4 (fr)
PT (1) PT2970467T (fr)
SG (1) SG11201506932SA (fr)
SI (1) SI2970467T1 (fr)
TN (1) TN2015000415A1 (fr)
TR (1) TR201900638T4 (fr)
TW (1) TWI644923B (fr)
UY (1) UY35440A (fr)
WO (1) WO2014151644A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3345620B1 (fr) 2009-05-13 2024-08-28 Genzyme Corporation Procédés et compositions permettant de traiter le lupus
KR101537840B1 (ko) 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
CN110351062B (zh) * 2014-01-28 2022-03-01 华为技术有限公司 数据传输的指示方法、接入点和终端
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
EP3752193A4 (fr) * 2018-02-13 2022-02-23 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
WO2021022044A1 (fr) * 2019-07-31 2021-02-04 Forty Seven, Inc. Régimes d'appauvrissement pour une thérapie à lymphocytes t ou à cellules nk modifiés
JPWO2024038839A1 (fr) * 2022-08-15 2024-02-22
WO2025149667A1 (fr) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT705833E (pt) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
CA2342967A1 (fr) 1998-12-08 2000-06-15 Biovation Limited Modification de l'immunogenicite de proteines
EP1242401B1 (fr) 1999-11-24 2006-12-27 Immunogen, Inc. Agents cytotoxiques comprenant des taxanes et leur utilisation therapeutique
NZ521182A (en) 2000-03-03 2004-11-26 Cambridge Antibody Tech Human antibodies against eotaxin comprising VH adn VL domains and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
EP1461423B1 (fr) 2001-12-03 2008-05-14 Amgen Fremont Inc. Categorisation d'anticorps reposant sur des caracteristiques de liaison
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042032A2 (fr) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Anomalies cytogenetiques qui permettent de predire la reponse a un traitement de la leucemie lymphoide chronique
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
KR20060002896A (ko) 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
PT1694706E (pt) 2003-11-01 2012-06-19 Merck Patent Gmbh Anticorpo anti-cd52 modificado
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
WO2006126068A2 (fr) 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd Methode recombinante pour la production d'un anticorps monoclonal dirige contre cd52 pour traiter une leucemie lymphocytique chronique
CN101247830B (zh) * 2005-05-27 2013-03-27 比奥根艾迪克Ma公司 结合tweak的抗体
DK1966244T3 (da) 2005-12-30 2012-04-23 Merck Patent Gmbh Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
EP2012814B1 (fr) 2006-04-12 2013-05-22 Genzyme Corporation Procédés de traitement des maladies auto-immunes
EP2433649A3 (fr) 2006-09-13 2012-10-31 Alcafleu Management GmbH & Co. KG Traitement de la sclerose en plaques (MS) par le campath-1H
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
WO2009000406A1 (fr) 2007-06-22 2008-12-31 Bayer Healthcare Ag Utilisation d'anticorps dirigés contre l'antigène cd52 pour le traitement de troubles neurologiques, en particulier l'encéphalopathie spongiforme transmissible et la maladie d'alzheimer
KR101537840B1 (ko) * 2009-05-13 2015-07-22 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
EP3345620B1 (fr) 2009-05-13 2024-08-28 Genzyme Corporation Procédés et compositions permettant de traiter le lupus
TWI502068B (zh) * 2009-07-15 2015-10-01 Aimm Therapiutics B V 革蘭氏陽性菌特異性結合的化合物
DK3336225T3 (da) * 2010-07-16 2020-03-30 Adimab Llc Antistofbiblioteker

Also Published As

Publication number Publication date
WO2014151644A2 (fr) 2014-09-25
JP2016518333A (ja) 2016-06-23
US20170349665A1 (en) 2017-12-07
PE20151757A1 (es) 2015-12-03
ES2710976T3 (es) 2019-04-29
PT2970467T (pt) 2019-01-28
HRP20190085T1 (hr) 2019-03-08
NZ631473A (en) 2017-09-29
TW201522373A (zh) 2015-06-16
GT201500267A (es) 2017-12-15
WO2014151644A3 (fr) 2015-01-15
DK2970467T3 (en) 2019-02-11
DOP2015000211A (es) 2015-11-30
TN2015000415A1 (en) 2017-01-03
EA201591796A1 (ru) 2016-01-29
BR112015022464A2 (pt) 2017-10-24
PL2970467T3 (pl) 2019-07-31
US20160024219A1 (en) 2016-01-28
MX2015012991A (es) 2015-12-15
SI2970467T1 (sl) 2019-03-29
HK1219963A1 (en) 2017-04-21
HUE041796T2 (hu) 2019-05-28
EP2970467B1 (fr) 2018-10-17
AU2014233685A1 (en) 2015-10-01
AU2014233685B2 (en) 2019-02-28
CA2906539A1 (fr) 2014-09-25
AR095199A1 (es) 2015-09-30
CL2015002705A1 (es) 2016-04-22
UY35440A (es) 2014-10-31
LT2970467T (lt) 2019-02-11
PL2970467T4 (pl) 2019-07-31
KR20150131286A (ko) 2015-11-24
PH12015501932A1 (en) 2016-01-04
TWI644923B (zh) 2018-12-21
CR20150547A (es) 2016-01-08
JP2019069960A (ja) 2019-05-09
IL241410A0 (en) 2015-11-30
EA031730B1 (ru) 2019-02-28
US9708407B2 (en) 2017-07-18
JP6482524B2 (ja) 2019-03-13
SG11201506932SA (en) 2015-09-29
CN105209495A (zh) 2015-12-30
CY1121795T1 (el) 2020-07-31
CN105209495B (zh) 2020-06-26
TR201900638T4 (tr) 2019-03-21
EP2970467A2 (fr) 2016-01-20

Similar Documents

Publication Publication Date Title
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
EP3565846A4 (fr) Agents thérapeutiques protéiques pour le traitement de cellules sénescentes
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MA38478A1 (fr) Anticorps anti-pac1 humains
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
PH12016502590B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
MA41596B1 (fr) Anticorps anti-tau et leurs utilisations
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MA39342B2 (fr) Anticorps il -21
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MA44948A1 (fr) Inhibiteurs de bace 1
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
EA202192460A1 (ru) Синтетические нейромодуляторные пептиды
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques